Bénin on track to join top tier of WHO’s pharmaceutical regulation leaders
In a landmark move for Africa’s healthcare landscape, Bénin has taken a giant leap toward securing a coveted certification from the World Health Organization (WHO). Between July 6 and 9, 2026, the Bénin Agency for Medicines and Health Products (ABMed) underwent a comprehensive evaluation by a high-level WHO delegation. The four-day scrutiny assessed every facet of the country’s pharmaceutical regulatory framework—from drug approval processes to post-market surveillance and clinical trials.
Rigorous assessment paves the way for global recognition
The WHO team, composed of eight international experts, meticulously reviewed ABMed’s operations, legal frameworks, and compliance mechanisms. Their goal? To determine if Bénin’s systems align with the WHO’s stringent regulatory standards. The findings, presented in Cotonou on July 9, revealed promising progress, signaling that the country is inching closer to securing the WHO Maturity Level 3 (ML3) certification.
This level is not merely a bureaucratic milestone—it’s a testament to a nation’s ability to guarantee safe, high-quality medicines for its citizens. For Bénin, achieving ML3 would mean gaining full control over its pharmaceutical supply chain, effectively curbing the spread of counterfeit drugs and enhancing public health outcomes.
A decade of reform culminates in international acclaim
The journey to this point began in 2017, when the government launched sweeping reforms to overhaul the pharmaceutical sector. By dismantling outdated structures and establishing ABMed as an autonomous regulatory body, authorities laid the groundwork for a modern, transparent healthcare system. The reforms also included stricter legislation to strengthen drug safety protocols and promote local pharmaceutical production.
During the evaluation’s closing session, Health Minister Professor Benjamin Hounkpatin lauded the efforts of ABMed’s teams, emphasizing that this progress reflects years of dedication. He reaffirmed the government’s commitment to supporting the agency until the final certification is secured, calling it a “historic achievement for Bénin’s healthcare sovereignty.”
Regional leadership in healthcare governance
If the WHO grants Bénin the ML3 certification, the country will join an elite group of West African nations leading the continent’s pharmaceutical regulation. Currently, only Senegal holds this distinction in francophone West Africa, making Bénin’s potential certification a game-changer for the subregion. Such recognition would position Bénin as a hub for pharmaceutical excellence, attracting investment and fostering collaboration with global health partners.
The certification process, however, is not yet complete. ABMed must now implement the remaining recommendations to finalize its compliance with WHO standards. Yet, the signs are encouraging: Bénin’s proactive reforms and unwavering political will have set a new benchmark for healthcare governance in Africa.
What the WHO Maturity Level 3 means for Bénin’s future
Beyond the immediate benefits of improved drug safety, ML3 certification carries long-term advantages. It would boost investor confidence, streamline regional trade in pharmaceuticals, and reinforce Bénin’s role as a trusted partner in global health initiatives. For the average citizen, it translates to greater access to affordable, high-quality medicines and a stronger defense against counterfeit pharmaceuticals—a persistent threat in many African nations.
The July 2026 WHO evaluation marks a turning point. While the final decision is pending, the evidence strongly suggests that Bénin is on the cusp of joining the ranks of the world’s most reliable pharmaceutical regulators. This achievement would not only safeguard public health but also serve as a model for other African nations striving to align their health systems with global best practices.
